Acalabrutinib
D822BC00001
Phase 3 small_molecule active
Quick answer
Acalabrutinib for Untreated Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Untreated Chronic Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active